Journal of Cardiovascular Pharmacology最新文献_第6页

Drug Interaction of SGLT2Is and ARNI on Acute Kidney Injury: A Real-World Pharmacovigilance Analysis Through the FAERS. SGLT2Is和ARNI在急性肾损伤中的药物相互作用：通过FAERS进行现实世界药物警戒分析。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-01-01 DOI: 10.1097/FJC.0000000000001639

Subei Zhao, Ronghua He, Mei Mei, Meng Yu, Zheng Yang, Chunyan Tian, Ping Zhang, Rong Li

{"title":"Drug Interaction of SGLT2Is and ARNI on Acute Kidney Injury: A Real-World Pharmacovigilance Analysis Through the FAERS.","authors":"Subei Zhao, Ronghua He, Mei Mei, Meng Yu, Zheng Yang, Chunyan Tian, Ping Zhang, Rong Li","doi":"10.1097/FJC.0000000000001639","DOIUrl":"10.1097/FJC.0000000000001639","url":null,"abstract":"Abstract: Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) and angiotensin receptor-neprilysin inhibitor (ARNI) may cause potential renal damage, the combined impact of SGLT2Is and ARNI on acute kidney injury (AKI) remains unclear. This pharmacovigilance study conducted a disproportionality analysis using reports from the FDA Adverse Event Reporting System database. The reporting odds ratio was used as an estimate for detecting AKI signal. A total of 659,573 reports on at least 1 glucose-lowering drug and/or ARNI were obtained. Of the 413 reports on cotherapy of SGLT2Is and ARNI, 99 (24.0%) reports mentioned AKI. Overall, the AKI reporting rate significantly increased in cotherapy (adjusted reporting odds ratio, 95% confidence interval: 8.04, 6.20-10.42, P < 0.001), with a stronger AKI signal in cotherapy of canagliflozin and ARNI (16.82, 3.75-75.57, P < 0.001). Specifically, no increased AKI signal was detected in patients with heart failure (HF) receiving cotherapy after adjustment for sex and age (HF: 1.27, 0.89-1.80, P = 0.189; HF plus diabetes: 2.08, 0.99-4.40, P = 0.055; or HF plus hypertension: 1.69, 0.53-5.35, P = 0.376), whereas enhanced AKI signals were detected in patients with diabetes (20.57, 11.93-35.46, P < 0.001), hypertension (4.30, 1.98-9.37, P < 0.001), or diabetes plus hypertension (5.44, 1.92-15.43, P = 0.001). This study reveals that superimposed renal impairment results from cotherapy with SGLT2Is and ARNI. It is necessary to be vigilant that the elderly patients with diabetes, hypertension, or chronic kidney disease are more susceptible to AKI, especially if they likewise receive diuretics. When cotherapy is unavoidable, early monitoring of renal function, blood volume, and blood pressure is excessively crucial. However, it is relatively safe in patients with HF.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"44-53"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Potential Impact of Renin-Angiotensin System Inhibitors on Cancer Survival and Recurrence: A Systemic Review and Meta-Analysis. 肾素-血管紧张素系统抑制剂对癌症生存和复发的潜在影响：系统回顾与荟萃分析。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-01-01 DOI: 10.1097/FJC.0000000000001600

Kaneez Fatima, Aayat Ellahi, Mariam Adil, Haider Kashif, Muhammad Uzair, Naela Ashraf, Mehak Barolia, Mujtaba Hyder, Areeba Nakhuda, Michelle Ayub, Sofia Jamil Butt, Ahmed Mustafa Rashid

{"title":"The Potential Impact of Renin-Angiotensin System Inhibitors on Cancer Survival and Recurrence: A Systemic Review and Meta-Analysis.","authors":"Kaneez Fatima, Aayat Ellahi, Mariam Adil, Haider Kashif, Muhammad Uzair, Naela Ashraf, Mehak Barolia, Mujtaba Hyder, Areeba Nakhuda, Michelle Ayub, Sofia Jamil Butt, Ahmed Mustafa Rashid","doi":"10.1097/FJC.0000000000001600","DOIUrl":"10.1097/FJC.0000000000001600","url":null,"abstract":"Abstract: Renin-angiotensin system inhibitors (RASis), specifically angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs), are widely used antihypertensives. Their impact on the prognostic outcomes among patients with cancer has been subject to scrutiny and debate. The aim of this study was to evaluate the effect of RASis on survival in patients with cancer.We systematically searched PubMed, Web of Science, Embase, and Cochrane Library for relevant studies published until April 1, 2022. All the studies, interventional or observational, which examined effects of ARBs and ACEis on cancer prognosis compared with a control group and reported the survival outcomes and hazard ratios were included in the analysis. From each study, pooled hazard ratios (HRs) with corresponding 95% confidence intervals (95% CIs) were identified and collected. Subgroup analysis was conducted to investigate heterogeneity.61 studies were included in this meta-analysis. Data of 343,283 participants were used in the study. It was found that RASis improved overall survival (HR = 0.88; 95% CI, 0.82-0.93; P < 0.0001), progression-free survival (HR = 0.72; 95% CI, 0.65-0.79; P < 0.00001), disease-specific survival (HR = 0.86; 95% CI, 0.71-1.04; P = 0.03), and recurrence-free survival (HR = 0.74; 95% CI, 0.58-0.93; P = 0.01) in patients with cancer. The effect of RASis on overall survival varied depending on the type of cancer or type of RASis (ACEis or ARBs), according to subgroup analysis.The usage of renin-angiotensin system inhibitors has a positive impact on survival outcomes and recurrence among patients with cancer.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"35-43"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141723716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modulating Sympathetic Nervous System With the Use of SGLT2 Inhibitors: Where There Is Smoke, There Is Fire? 使用 SGLT2 抑制剂调节交感神经系统：哪里有烟，哪里就有火？

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-01-01 DOI: 10.1097/FJC.0000000000001644

Kyriakos Dimitriadis, Daphne Pitsiori, Polyxeni Alexiou, Nikolaos Pyrpyris, Athanasios Sakalidis, Eirini Beneki, Panagiotis Iliakis, Fotis Tatakis, Panagiotis Theofilis, Panagiotis Tsioufis, Dimitrios Konstantinidis, Konstantina Aggeli, Konstantinos Tsioufis

{"title":"Modulating Sympathetic Nervous System With the Use of SGLT2 Inhibitors: Where There Is Smoke, There Is Fire?","authors":"Kyriakos Dimitriadis, Daphne Pitsiori, Polyxeni Alexiou, Nikolaos Pyrpyris, Athanasios Sakalidis, Eirini Beneki, Panagiotis Iliakis, Fotis Tatakis, Panagiotis Theofilis, Panagiotis Tsioufis, Dimitrios Konstantinidis, Konstantina Aggeli, Konstantinos Tsioufis","doi":"10.1097/FJC.0000000000001644","DOIUrl":"10.1097/FJC.0000000000001644","url":null,"abstract":"Heart failure (HF) has become even more prevalent in recent years, because of improved diagnostics and an increase in the risk factors predisposing to its pathology. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) emerged as one of the key pharmacotherapy options for both reduced and preserved ejection fraction, providing cardio- and renoprotection and improving mortality and cardiovascular (CV) outcomes. The pleiotropism of SGLT2i has led to multiple efforts to understand their distinct pathophysiologic interactions with various pathways, including microcirculation, endothelial dysfunction, and inflammation. More recently, the role of SGLT2i on the sympathetic nervous system (SNS) is starting to be recognized, especially because observations of retained or reduced heart rate despite volume contraction have been noted by investigators in the large clinical trials testing the safety and efficacy of these agents. Both preclinical and clinical studies have been performed, with conflicting results. Interestingly, in both settings, although there are indications of SNS modulation by SGLT2i, other studies contradict such findings, without showing, however, worsening of the autonomic homeostasis. Given the importance of neuromodulation in HF, in both pharmacologic and interventional therapies, in this review, we aim to describe the role of SNS in CV disease, focusing on HF, analyze preclinical and clinical data regarding the efficacy of SGLT2i in modulating autonomic dysfunction by examining various markers of SNS activation, and provide the most plausible theoretical backgrounds on the mechanism of benefit of SNS from the inhibition of SGLT2 receptors.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"12-20"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of Prolonged Cold Stress on Vascular Function in Guinea Pigs With Atherosclerosis. 长期冷应激对动脉粥样硬化豚鼠血管功能的影响

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-01-01 DOI: 10.1097/FJC.0000000000001645

Wen-Xiang Guan, Zhuo Lan, Qing-Chun Wang, Hao Ri Wa, Huhe Muren, Li-Li Bai, Si Ri Men, Guo-Qing Liu, Jing-Xian Gao, Chang-Xi Bai

{"title":"Effects of Prolonged Cold Stress on Vascular Function in Guinea Pigs With Atherosclerosis.","authors":"Wen-Xiang Guan, Zhuo Lan, Qing-Chun Wang, Hao Ri Wa, Huhe Muren, Li-Li Bai, Si Ri Men, Guo-Qing Liu, Jing-Xian Gao, Chang-Xi Bai","doi":"10.1097/FJC.0000000000001645","DOIUrl":"10.1097/FJC.0000000000001645","url":null,"abstract":"Research objective: This study explored the effects of long-term cold stress (CS) on aortic vascular function in guinea pigs.Research methods: Hartley guinea pigs (n = 32) were divided into the following groups: atherosclerosis (AS), CS, and menthol-stimulated (M), and control (C). On days 1, 15, 30, 45, and 60, guinea pigs in the AS, CS, and M groups were intraperitoneally injected with bovine serum albumin. The C group was provided with maintenance feed and room temperature water. The AS group was provided with a high-fat diet and room temperature water. The CS group was maintained in a refrigerator at 4°C, while providing a high-fat diet and iced water. The M group was administered menthol solution, and provided with a high-fat diet and room temperature water. The modeling period lasted for 120 days. On day 121, abdominal aortic sera and aortic samples were obtained after intraperitoneal injection of sodium pentobarbital. Blood rheology tests were conducted to assess blood adhesion, biochemical tests to assess lipid levels, and enzyme-linked immunosorbent assays to detect serum nuclear factor-κB, tumor necrosis factor-α, and interleukin-1β, and endothelial nitric oxide synthase, nitric oxide, and endothelin-1 (ET-1) in aortic tissue. Hematoxylin and eosin and oil red O staining were used to examine pathologic changes in the aorta, Western blotting to detect transient receptor potential melastatin 8 and protein kinase G protein expression, quantitative polymerase chain reaction was used to measure VCAM-1 mRNA expression level.Research findings: Prolonged exposure to CS exacerbated lipid-metabolism disorders in guinea pigs fed a high-fat diet, increased aortic vascular cell adhesion, and exacerbated vascular inflammation, leading to endothelial injury, ultimately worsening pathologic changes associated with aortic atherosclerosis.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"63-74"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deubiquitinase USP47 Ameliorates Cardiac Hypertrophy Through Reducing Protein O-GlcNAcylation. 去泛素化酶 USP47 通过减少蛋白质 O-GlcNAcylation 改善心肌肥大。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2025-01-01 DOI: 10.1097/FJC.0000000000001640

Yu Jiang, Wenyao Cai, Guangtao Lei, Guorong Cai, Qinghua Wu, Peng Lu

{"title":"Deubiquitinase USP47 Ameliorates Cardiac Hypertrophy Through Reducing Protein O-GlcNAcylation.","authors":"Yu Jiang, Wenyao Cai, Guangtao Lei, Guorong Cai, Qinghua Wu, Peng Lu","doi":"10.1097/FJC.0000000000001640","DOIUrl":"10.1097/FJC.0000000000001640","url":null,"abstract":"Abstract: Cardiac hypertrophy is a crucial risk factor for heart failure when the heart is confronted with physiologic or pathologic stimuli. The ubiquitin-proteasome system plays a critical role in the pathogenesis of cardiac hypertrophy. However, as a key component of the ubiquitin-proteasome system, the role of deubiquitinating enzymes in cardiac hypertrophy is not well understood. In this study, we observed that the expression level of deubiquitinase USP47 was increased in hypertrophic hearts and angiotensin II (Ang II)-stimulated neonatal rat cardiomyocytes. Adenovirus-mediated gain- and loss-of-function approaches indicated that USP47 overexpression significantly attenuated Ang II-induced cardiac hypertrophy in vitro and in vivo, whereas endogenous USP47 deficiency promoted the prohypertrophic effect of Ang II. Further investigation demonstrated that USP47 inhibited O-GlcNAcylation in cardiomyocytes by controlling the expression of O-GlcNAcase. Mechanistically, USP47 bound, deubiquitinated, and stabilized protein arginine methyltransferase 5 (PRMT5), thus upregulating O-GlcNAcase expression. We found that the restoration of PRMT5 abolished the prohypertrophic effects of USP47 silence in vitro. Therefore, our results provide the first evidence of the involvement of USP47 in cardiac hypertrophy and identify USP47 as a potential target for hypertrophic therapy.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"54-62"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142466352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug-induced Spontaneous intramural hematoma of the gastrointestinal tract: A real-world pharmacovigilance analysis. 药物引起的自发性胃肠道血肿：现实世界的药物警戒分析。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-12-31 DOI: 10.1097/FJC.0000000000001662

Xuehong Wang, Min Luo, Wenyu Li, Yuqian Zhou

{"title":"Drug-induced Spontaneous intramural hematoma of the gastrointestinal tract: A real-world pharmacovigilance analysis.","authors":"Xuehong Wang, Min Luo, Wenyu Li, Yuqian Zhou","doi":"10.1097/FJC.0000000000001662","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001662","url":null,"abstract":"It is unclear whether drugs other than warfarin can cause spontaneous gastrointestinal intraluminal hematomas (SGIH). This study aimed to investigate the drugs that induced SGIH based on the FDA Adverse Event Reporting System (FAERS) data. A retrospective pharmacovigilance study was conducted. The disproportionality analysis was performed to assess the reports of drug-induced SGIH from the first quarter of 2004 to the fourth quarter of 2023. Logistics regression analysis was used to explore drug-related SGIH risk factors. Weibull distribution was applied for the onset time of SGIH. A total of 116 drugs associated with SGIH have been reported in the FAERS database. After removing duplicates, 88 unique drugs involving 210 patients were identified. These drugs can be broadly classified into four categories: (1) anticoagulants, (2) new direct oral anticoagulants, (3) antiplatelet agents, and (4) others. The first group is dominated by warfarin (59/210), while the second group, rivaroxaban, accounts for the most significant proportion (9/210). As for the third group, aspirin is the dominant drug (16/210), and for the fourth group, drugs that cause thrombocytopenia are dominant. The median number of reported cases was 11.5 per year, accounting for a median percentage of 0.0094% of all adverse events related to target drugs. The median time to drug-related SGIH onset was 12.5 days (interquartile range 1-220.25 days). When patients on the related drugs present with corresponding abdominal symptoms, it is crucial to consider the differential diagnosis of SGIH despite its low incidence.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142909705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mineralocorticoid receptor antagonist vs. placebo in a patient with end-stage kidney disease under renal replacement therapy: a systematic review and meta-analysis. 矿皮质激素受体拮抗剂与安慰剂在肾替代治疗的终末期肾病患者中的应用：系统回顾和荟萃分析

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-12-12 DOI: 10.1097/FJC.0000000000001661

Sagun Dawadi, Dhan Bahadur Shrestha, Prakash Raj Oli, Jurgen Shtembari, Sajog Kansakar, Suman Paudel, Kailash Pant

{"title":"Mineralocorticoid receptor antagonist vs. placebo in a patient with end-stage kidney disease under renal replacement therapy: a systematic review and meta-analysis.","authors":"Sagun Dawadi, Dhan Bahadur Shrestha, Prakash Raj Oli, Jurgen Shtembari, Sajog Kansakar, Suman Paudel, Kailash Pant","doi":"10.1097/FJC.0000000000001661","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001661","url":null,"abstract":"The number of patients living with chronic kidney diseases is increasing, and so are the patients with end-stage renal disease (ESRD) undergoing renal replacement therapy (RRT). While there is a common understanding that these patients face higher risks of fatal or non-fatal cardiovascular and cerebrovascular events, and mineralocorticoid receptor antagonists (MRA) have been an essential pillar in managing heart failure, their use in this subset of patients have been overshadowed due to concerns of hyperkalemia. ESRD patients under RRT have often been excluded from landmark trials. This meta-analysis was conducted based on the PRISMA guideline after registering the protocol with PROSPERO (CRD42024499835). A database search included articles until April 2024 and relevant data extracted from the included studies. Analysis was done using RevMan web (version 5.4). A total of 15 studies among 1086 studies were included in the final analysis. Our meta-analysis revealed MRA significantly reduced all-cause mortality (OR 0.35, CI 0.23- 0.54) and cardio-vascular mortality (OR 0.37, 0.21-0.65). With some possible increase in the risk of hyperkalemia (OR 1.56, CI 1.01-2.42), with no discernible difference in the occurrence of stroke (OR 0.57, CI 0.25-1.28) or MI (OR 0.63, CI 0.08-4.72). The utilization of MRA in patients with ESRD under dialysis is linked to improved mortality outcomes, albeit with slight concerns for hyperkalemia. While current evidence leans towards MRA usage, prospective randomized controlled trials involving a broader patient cohort are essential to establish robust guidance for MRA application in this subset of patients.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparing the efficacy of sodium-glucose co-transporter 2 inhibitors among non-older and older patients: A Systematic Review and Meta-Analysis. 比较钠-葡萄糖共转运蛋白2抑制剂在非老年和老年患者中的疗效：一项系统回顾和荟萃分析

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-12-12 DOI: 10.1097/FJC.0000000000001659

Izuki Yamashita, Tomohiro Fujisaki, Francisco J Romeo, Daisuke Sueta, Eiichiro Yamamoto, Kenichi Tsujita

{"title":"Comparing the efficacy of sodium-glucose co-transporter 2 inhibitors among non-older and older patients: A Systematic Review and Meta-Analysis.","authors":"Izuki Yamashita, Tomohiro Fujisaki, Francisco J Romeo, Daisuke Sueta, Eiichiro Yamamoto, Kenichi Tsujita","doi":"10.1097/FJC.0000000000001659","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001659","url":null,"abstract":"Large scale randomized trials have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors can reduce cardiovascular events in patients with cardiovascular disease or with increased risks of cardiovascular disease. However, the evidence from older patients is limited. To compare the efficacy of SGLT2 inhibitors among non-older and older patients we have searched PubMed, Cochrane Central, and Embase until February 2023 for randomized controlled trials (RCTs) investigating SGLT2 inhibitors in older (age ≥ 65 years) patients with diabetes mellitus, chronic kidney disease, and chronic heart failure. The primary outcome was a composite outcome of cardiovascular death, acute myocardial infarction, and stroke. The secondary outcomes were exacerbation of heart failure, kidney disease progression, and a composite of cardiovascular death and heart failure. Our search identified 11 RCTs with a total of 79,370 patients. SGLT2 inhibitors were associated with a reduced risk of the primary outcome in the total cohort (HR: 0.91; CI [0.84-0.99]) with concordant results in both non-older and older populations (HR: 0.96; CI [0.88-1.05], HR: 0.87; CI [0.75-1.01], respectively) without subgroup differences (p=0.23), and a reduced risk of developing the composite of cardiovascular death and heart failure exacerbation in both non-older and older populations (HR: 0.77; CI [0.67-0.87], HR: 0.76; CI [0.71-0.82], respectively) without subgroup differences (p=0.96). A meta-analysis could not be performed for the other outcomes. These results suggested that SGLT2 inhibitors were similarly associated with a reduced risks of cardiovascular events across the spectrum of non-older and older patients with risk factors for developing cardiovascular disease.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Finerenone Proves Beneficial for Heart Failure With Preserved Ejection Fraction. 非格列酮能有效治疗射血分数保留型心力衰竭。

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-12-01 DOI: 10.1097/FJC.0000000000001636

Giuseppe Biondi-Zoccai, Mattia Galli, George W Booz

引用次数: 0

Comparative Analysis of Anticoagulation Versus Combination Anticoagulation and Antiplatelet Therapy in Atrial Fibrillation Patients Presenting With Gastrointestinal Bleeding. 对出现消化道出血的心房颤动患者进行抗凝与抗凝及抗血小板联合疗法的比较分析

IF 2.6 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2024-12-01 DOI: 10.1097/FJC.0000000000001641

Ali Dakroub, Hadi Beaini, Ramzi Kibbi, Mohamad B Moumneh, Saleem M Halablab, Razan Dankar, Nour Adra, Chantal Rizk, Kassem Barada, Marwan Refaat

{"title":"Comparative Analysis of Anticoagulation Versus Combination Anticoagulation and Antiplatelet Therapy in Atrial Fibrillation Patients Presenting With Gastrointestinal Bleeding.","authors":"Ali Dakroub, Hadi Beaini, Ramzi Kibbi, Mohamad B Moumneh, Saleem M Halablab, Razan Dankar, Nour Adra, Chantal Rizk, Kassem Barada, Marwan Refaat","doi":"10.1097/FJC.0000000000001641","DOIUrl":"10.1097/FJC.0000000000001641","url":null,"abstract":"Abstract: Patients with atrial fibrillation (AF) taking antithrombotic (AT) therapy are at an increased risk of gastrointestinal bleeding (GIB). The comparative effect of a combination of anticoagulant (AC) and antiplatelet (AP) versus AC monotherapy on clinical outcomes in patients with AF presenting with GIB is not well characterized. This study compares outcomes in AF patients with GIB on AC alone with those on combination AP and AC therapy, as part of a larger prospective study from 2013 to 2023. One hundred and thirty-seven patients diagnosed with AF who presented with overt GIB were evaluated during their hospitalization, at 1 month and 1 year postdischarge and then annually. The median follow-up of patients was 57 months. Patients in the combination AP + AC therapy group had a higher prevalence of coronary artery disease, myocardial infarction, and coronary/vascular stent placement compared with the AC monotherapy group. No statistically significant differences were noted between the 2 groups in terms of end-of-follow-up mortality, in-hospital mortality, major bleeding, rebleeding, and length of hospital stay. Cox regression analysis revealed chronic kidney disease [hazard ratio (HR) 2.05, 95% confidence interval (1.04-4.05) ( P = 0.038)] and warfarin use [HR 4.94, 95% confidence interval (1.11-22.09) ( P = 0.037)] to be independent predictors of mortality at 12 months. Antithrombotic therapy in patients with AF who experience GIB should be mainly directed by their cardiovascular needs. Health care providers may explore non-vitamin K antagonist oral anticoagulants as alternatives to warfarin for AF patients at risk of GIB, and efforts must be maximized to prevent bleeding in patients with chronic kidney disease.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"599-605"},"PeriodicalIF":2.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142400405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0